ArticleJournal of education and health promotion2026
Impact of growth hormone treatment on childhood growth patterns in Kermanshah: A retrospective cohort study.
Article in Journal of education and health promotion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShort stature is a major pediatric concern and a common reason for endocrinology referrals. Although recombinant human growth hormone (rhGH) is widely used to treat short stature, its high cost and variable consequences raise concerns about its rational use and long-term effectiveness. MATERIALS AND
methodsThis retrospective cohort study examined medical records of 260 children aged 3-15 years who received rhGH therapy in Kermanshah between March 2021 and March 2022. Attrition occurred due to physician decision, patient unwillingness to continue treatment, or incomplete records, leaving 54 patients eligible for analysis. This attrition highlights a source of selection bias and limits the generalizability of findings. Growth parameters were assessed across three treatment stages. Pearson correlation and repeated measures ANOVA were performed using SPSS version 22 (
resultsThe final cohort included 34 girls and 20 boys with a mean age of approximately 10.5 years. Repeated measures analysis demonstrated a significant increase in mean height z-score from the first to the third treatment stage. Pearson correlation showed no significant association between rhGH dose and growth response. Financial constraints and physician decisions were the main reasons for dropout.
conclusionrhGH therapy improved children's growth parameters independent of dosage intensity. However, the high dropout rate highlights the need for cautious interpretation of the results, as selection bias may have affected the observed results. Transparent reporting of dropout patterns and enhanced financial and clinical support systems are essential to promote equitable access to therapy and strengthen the validity and applicability of future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.